The €253 million co-funding scheme for AMR research and innovation will launch its first call in November
Photo credits: l i g h t p o e t / BigStock
Horizon Europe’s partnership for antimicrobial resistance (AMR) research launched last week with a plan to bring Europe closer to finding new anti-microbial therapies in the next decade. With more of an innovation focus than its Horizon 2020 predecessor, the aim is to move potential therapies closer to the market.
The ten-year partnership pools €253 million in research funding from 30 countries, including €75 million from Horizon Europe. Its first call, focused on treatments, is due to launch in November with a budget of around €35 million. The call text has yet to be published, but a pre-announcement is due in mid-October.
Treatment is one of three focus areas outlined it the partnership’s https://www.jpiamr.eu/app/uploads/2024/09/EUP-OHAMR-SRIA_draft-2024…
Discover the latest in research funding every Tuesday with Funding Newswire. Dive into detailed articles with our monthly or yearly subscriptions or start with a free trial
NOTE: if you're a part of one of our Network member organisations, you get free access by signing up with your institutional email. Verify your eligibility here.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.